India Pharma Outlook Team | Friday, 26 September 2025
Evonik has announced the launch of MaxiPure Polysorbate 80, a highly pure surfactant specifically designed for injectable and biopharmaceutical formulations. Modified to satisfy the strict requirements of current pharmaceuticals development, MaxiPure helps in a number of ways omitting the solvating agents in protein stability, viral inactivation, and solubilization of hydrophobic active pharmaceutical ingredients (API) with the unchanging character.
With this new introduction, the German company further supports the biopharmaceutical sector with the delivery of high-quality and well-established excipients that are compatible with the trend of new biologics and biosimilars.
“MaxiPure Polysorbate 80 is a strategic addition to our excipient portfolio. Its outstanding purity, together with our diligent regulatory support, sends the message that we are ready to help our customers in the most difficult injectable formulations and bioprocess challenges,” stated Guido Skudlarek, Head of the Health Care business line at Evonik.
Polysorbate 80 is one of the most frequently used non-ionic surfactants in pharmaceutical formulations. In traditional qualities, peroxide levels are usually higher and partial fatty acid esters are variable which may lead to batch-to-batch inconsistencies, oxidative degradation, and instability of sensitive APIs or proteins. To avoid these disadvantages, Evonik has developed MaxiPure Polysorbate 80 that is characterized by its ultra-high purity with the content of oleic acid being more than 98%, exceptional clarity, and also fully complying with Ph. Eur., USP, JP, and CP requirements.
Also Read: Pfizer Showcases Breakthrough Oncology Data at ESMO 2025
Innovated to fulfill the strictest standards of biopharmaceutical manufacturing, MaxiPure not only ensures a higher level of a formulation's reliability and reproducibility but also guarantees worldwide regulatory confidence, thus being the best choice for costly injectable and biopharmaceutical applications.
